<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04878107</url>
  </required_header>
  <id_info>
    <org_study_id>2021061</org_study_id>
    <nct_id>NCT04878107</nct_id>
  </id_info>
  <brief_title>SBRT/LDRT in Combination With Camrelizumab and Apatinib in Metastatic Non-small Cell Lung Cancer Patient Previously Treated With PD-1/L1 Inhibitor and Chemotherapy</brief_title>
  <acronym>SABRE</acronym>
  <official_title>SBRT/LDRT in Combination With Camrelizumab and Apatinib in Metastatic Non-small Cell Lung Cancer Patient Previously Treated With PD-1/L1 Inhibitor and Chemotherapy：a Prospective Exploratory Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Wuhan University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Wuhan University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      SABRE STUDY will explore effectiveness and safety of the combination therapy of&#xD;
      camrelizumab，apatinib and SBRT/LDRT in patients with metastatic non-small Cell Lung Cancer&#xD;
      (NSCLC) patient previously treated With PD-1/L1 Inhibitor and Chemotherapy.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      SABRE STUDY consists of two stages.&#xD;
&#xD;
      first stage of this trial is a single-arm study that requires enrolling at least 18 patients,&#xD;
      all of whom would receive the treatment of SBRT/LDRT in combination with apatinib plus&#xD;
      camrelizumab.The trial would proceed into the second stage if 4 or more patients achieve&#xD;
      CR/PR. Otherwise, the trial is stopped early due to futility as we fail to reject the null.&#xD;
&#xD;
      In the second stage, at least 70 patients are equally randomized into two arms to receive&#xD;
      &quot;SBRT/LDRT in combination with apatinib plus camrelizumab&quot; or &quot;SBRT + docetaxel&quot; .&#xD;
      Stratified-area group randomization would be used.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">October 2021</start_date>
  <completion_date type="Anticipated">October 2023</completion_date>
  <primary_completion_date type="Anticipated">October 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Objective response rate</measure>
    <time_frame>6 Weeks</time_frame>
    <description>Objective Response Rate at 6 months using RECIST1.1 criteria</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Duration Response Rate</measure>
    <time_frame>6 Weeks</time_frame>
    <description>ime from the date of the first documented response (CR or PR) to the earliest date of disease progression (RECIST 1.1), or death due to any cause.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free Survival</measure>
    <time_frame>6 Weeks</time_frame>
    <description>Time from enrollment to first observation of progression (RECIST1.1) or date of death (from any cause)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>6 Weeks</time_frame>
    <description>Time from enrollment until death due to any cause</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>incidence, type and severity of adverse events</measure>
    <time_frame>From time of informed consent through treatment period and up to 30 days post last dose of study treatment (about 24 months)</time_frame>
    <description>Descriptive statistics of safety will be presented using National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE), version 5.0</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">88</enrollment>
  <condition>Non-Small Cell Lung Cancer</condition>
  <arm_group>
    <arm_group_label>SBRT/LDRT + Camrelizumab +Apatinib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>SBRT（8Gy×3f） LDRT（2Gy×5f） Camrelizumab（200mg，q3w） Apatinib （250mg，qd）</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SBRT + docetaxel</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>docetaxel 75mg/m2 SBRT（8Gy×3f）</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Camrelizumab</intervention_name>
    <description>Camrelizumab (AiRuiKa™), a programmed cell death 1 (PD-1) inhibitor being developed by Jiangsu Hengrui Medicine Co. Ltd</description>
    <arm_group_label>SBRT/LDRT + Camrelizumab +Apatinib</arm_group_label>
    <other_name>SHR1210</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Apatinib</intervention_name>
    <description>Apatinib [Aitan® (brand name in China)], also known as rivoceranib, is a novel, small molecule, selective vascular endothelial growth factor receptor-2 (VEGFR-2) tyrosine kinase inhibitor</description>
    <arm_group_label>SBRT/LDRT + Camrelizumab +Apatinib</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Docetaxel injection</intervention_name>
    <description>Docetaxel is an anti-cancer (&quot;antineoplastic&quot; or &quot;cytotoxic&quot;) chemotherapy drug</description>
    <arm_group_label>SBRT + docetaxel</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>SBRT</intervention_name>
    <description>Stereotactic body radiation therapy (SBRT) is a cancer treatment that delivers extremely precise, very intense doses of radiation to cancer cells while minimizing damage to healthy tissue. SBRT involves the use of sophisticated image guidance that pinpoints the exact three-dimensional location of a tumor so that the radiation can be more precisely delivered to cancer cells.</description>
    <arm_group_label>SBRT + docetaxel</arm_group_label>
    <arm_group_label>SBRT/LDRT + Camrelizumab +Apatinib</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>LDRT</intervention_name>
    <description>low dose radation therapy</description>
    <arm_group_label>SBRT/LDRT + Camrelizumab +Apatinib</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Histological or cytological diagnosis of non-small cell lung cancer（NSCLC）&#xD;
&#xD;
          -  Has previous treatment with PD-1/L1 monoclonal antibody in combination with a&#xD;
             platinum-based chemotherapy with outcome of complete remission (CR), partial remission&#xD;
             (PR), or stable disease (SD) for ≥ 6 months&#xD;
&#xD;
          -  Has at least two disseminated lesions for LDRT and SBRT, respectively&#xD;
&#xD;
          -  Has a performance status of 0 or 1 on the Eastern Cooperative Oncology Group (ECOG)&#xD;
             Performance Status&#xD;
&#xD;
          -  Has confirmation that epidermal growth factor receptor (EGFR) or anaplastic lymphoma&#xD;
             kinase (ALK) or ROS Proto-Oncogene 1(ROS1)-directed therapy is not indicated&#xD;
&#xD;
          -  Has adequate organ function&#xD;
&#xD;
          -  For female subjects of childbearing potential, a serum pregnancy test should be&#xD;
             performed within 7 days prior to the administration of the first study intervention&#xD;
             (study drug, radiation therapy) and have a negative result. Subjects are required to&#xD;
             agree to use highly effective contraception (i.e., a method with a failure rate of&#xD;
             less than 1% per year) and continue until at least 180 days after discontinuation of&#xD;
             trial treatment&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Imaging (CT or MRI) shows evidence of tumour invasion of large blood vessels or poorly&#xD;
             demarcated blood vessels or the presence of cavities and necrotic lesions in the lungs&#xD;
&#xD;
          -  With active bleeding or perforation or a hereditary or acquired bleeding tendency&#xD;
             present, with a daily haemoptysis of ≥2.5mL in the 3 months prior to screening.&#xD;
&#xD;
          -  with hypertensive disorders that cannot be reduced to the normal range with&#xD;
             antihypertensive medication (systolic blood pressure ≤ 140 mmHg / diastolic blood&#xD;
             pressure ≤ 90 mmHg).&#xD;
&#xD;
          -  Urine routine suggesting urine protein ≥ (++) and 24-hour urine protein amount ≥ 1.0g.&#xD;
&#xD;
          -  presence of thrombotic disease requiring long-term anticoagulation with warfarin or&#xD;
             heparin, or requiring long-term antiplatelet therapy (aspirin ≥ 300 mg/day or&#xD;
             clopidogrel ≥ 75 mg/day).&#xD;
&#xD;
          -  Previous systemic antitumour therapy other than PD-1(L1) monoclonal antibody in&#xD;
             combination with platinum-based chemotherapy, or previous treatment with&#xD;
             anti-angiogenic agents (including bevacizumab, apatinib, anlotinib, etc.).&#xD;
&#xD;
          -  Immune-related adverse events in previous PD-1(L1) therapy leading to treatment&#xD;
             discontinuation&#xD;
&#xD;
          -  Symptomatic, untreated or actively progressing central nervous system (CNS) metastases&#xD;
             are confirmed by CT or MRI assessment during screening and prior to radiographic&#xD;
             evaluation.&#xD;
&#xD;
          -  Subjects with grade II or above myocardial ischemia or myocardial infarction and&#xD;
             poorly controlled arrhythmias (QTc interval &gt; 450 ms for males and QTc interval &gt; 470&#xD;
             ms for females). Subjects with grade III-IV cardiac insufficiency or with left&#xD;
             ventricular ejection fraction (LVEF) less than 50% according to NYHA criteria&#xD;
&#xD;
          -  Has known history of Human Immunodeficiency Virus (HIV)&#xD;
&#xD;
          -  Untreated active hepatitis B&#xD;
&#xD;
          -  Subjects have active hepatitis B&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>CongHua Xie, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Wuhan University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>You Lu, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>West China Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>CongHua Xie, MD</last_name>
    <phone>02767812510</phone>
    <phone_ext>86</phone_ext>
    <email>chxie_65@hotmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Zhongnan Hospital of Wuhan University</name>
      <address>
        <city>Wuhan</city>
        <state>Hubei</state>
        <zip>430071</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Conghua Xie, Dr</last_name>
      <phone>0086-27-67812607</phone>
      <email>chxie_65@whu.edu.cn</email>
    </contact>
    <contact_backup>
      <last_name>Yu Xu, Dr</last_name>
      <phone>0086-27-67812607</phone>
      <email>xuyu@whu.edu.cn</email>
    </contact_backup>
    <investigator>
      <last_name>Conghua Xie, Dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Yu Xu, Dr</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>May 4, 2021</study_first_submitted>
  <study_first_submitted_qc>May 4, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">May 7, 2021</study_first_posted>
  <last_update_submitted>October 10, 2021</last_update_submitted>
  <last_update_submitted_qc>October 10, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 12, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Wuhan University</investigator_affiliation>
    <investigator_full_name>Conghua Xie,MD,PhD</investigator_full_name>
    <investigator_title>Director of Department of Radiation and Medical Oncology</investigator_title>
  </responsible_party>
  <keyword>stereotactic body radiotherapy</keyword>
  <keyword>Low-Dose Radiation Therapy</keyword>
  <keyword>Camrelizumab</keyword>
  <keyword>Apatinib</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Docetaxel</mesh_term>
    <mesh_term>Apatinib</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

